Join        Login             Stock Quote

Tuesday’s Market Recap (06/30/09)

 June 30, 2009 10:13 PM

The markets had a rough day, with the Dow Jones down 0.97% to close at 8447.00.  The NASDAQ and S&P closed at 1835.04 and 919.32 respectively, down 0.49% and 0.85%.  Gold and crude oil both headed to lower prices today, with gold settling at $927.40, and oil down $0.91 to settle at $69.89.  The 10-year saw prices fall with the yield ending at 3.537%. 

hrb released earnings yesterday, reporting a profit of $706.9 million, or $2.09 per share, better then the earnings of $543.6 million, or $1.66 per share, released the same period the year before.  H&R Block missed on revenue, reporting that revenue fell 2.9% to $2.47 billion as opposed to the average analyst estimate of $2.52 billion, H&R Block however did beat earnings estimate of $2.05 per share.  The company's tax unit was hurt as it saw a weak tax season, with revenues falling 3.2% in tax service revenue.  The company has noticed this fall in revenue, and as a result H&R Block's CEO Russ Smyth said that it would be combining its tax and corporate structures into one unit in an effort to cut costs.  This is another move by H&R to cut down its management structure to make the company more efficient.  These actions follow its recent elimination of its brokerage and loan services.  H&R Block expects to see fiscal 2010 earnings between $1.60 and $1.80 per share, with the street estimating earnings of $1.66 per share.

[Related -H & R Block Inc. (NYSE:HRB): Does Tax-Time Equal Go Time?]

In health care news, a federal jury in Texas ordered abt to pay rival Johnson & Johnson (jnj) $1.67 billion for patent infringement on J&J's arthritis drug, Remicade, which was infringed upon with Abbot's Humira.  Humira is Abbot's leading drug and accounts for $4.5 billion in revenue last year, or 15% of total revenue.  Johnson & Johnson was thrilled with the news and were happy that the court recognized its intellectual property with its arthritis drug.  Abbot said that they are disappointed with the verdict and are going to appeal the findings of the jury.  Abbot has seen great success recently, with a good part being attributed to Humira, it will be interesting to see how Abbot will handle and move on from this. The Conference Board announced that its index of consumer confidence in June fell to 49.3 from May's 54.8.  This is bad news, especially as economists believe that confidence below 50 following a month when it was above 50, indicating economic growth, changes the general feeling that the economy was starting to bottom out.  This is bad news as consumer spending is tied to consumer confidence and with these poor numbers this could severely affect GDP, as spending accounts for about 66% of GDP.  Economist and investors alike are looking for consistent economic data to indicate if the market is bottoming or not, and they have been presented with data that is mixed and therefore makes it hard to tell.- Matt Shannon

[Related -Can Abbvie Inc (NYSE:ABBV) Trump Gilead Sciences, Inc.'S (NASDAQ:GILD) HCV Lead?]

Disclosure: The fund the author is associated with is long ABT and JNJ.



Comments Closed

rss feed

Latest Stories

article imageOversold Airline Ready For A Quick Rebound

Trading countertrend moves can be profitable but risky, so it pays to line up as many factors as possible read on...

article imageWhat Is Your Sell Criteria?

Every stock market cycle has its darlings—the stocks investors believe can do no wrong.  I remember 1999 read on...

article imageUS Employment Growth Continued To Slow In April

Company payrolls increased by a lower-than-expected 171,000 last month, the US Labor Department reports–the read on...

article imageMake America Great Again

Our weekly commentaries provide Euro Pacific Capital's latest thinking on developments in the global read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.